← Back to Clinical Trials
Recruiting NCT06565143

NCT06565143 Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06565143
Status Recruiting
Phase
Sponsor Anhui Medical University
Condition Transcranial Alternating Current Stimulation
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-03-01
Primary Completion 2026-03-01

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Transcranial alternating current stimulationSham transcranial alternating current stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-03-01 with a primary completion date of 2026-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To investigate the clinical effect neural mechanism of transcranial alternating current stimulation in early Alzheimer's disease

Eligibility Criteria

Inclusion Criteria: 1. Subject diagnosed with early Alzheimer's disease or related diseases according to NIA-AA criteria. 2. Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia. 3. CDR score ≤ 2. 4. Subject under treatment by IAChE for at least 3 months. 5. psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months. Exclusion Criteria: 1. CDR \> 2 2. Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder). 3. History of head injury,stroke,or other neurologic disease. 4. Organic brain defects on T1 or T2 images. 5. History of seizures or unexplained loss of consciousness. 6. Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator. 7. Family history of medication refractory epilepsy. 8. History of substance abuse within the last 6 months.

Contact & Investigator

Central Contact

Kai Wang, PhD

✉ wangkai1964@126.com

📞 +86-0551-62922263

Frequently Asked Questions

Who can join the NCT06565143 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Transcranial Alternating Current Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06565143 currently recruiting?

Yes, NCT06565143 is actively recruiting participants. Contact the research team at wangkai1964@126.com for enrollment information.

Where is the NCT06565143 trial being conducted?

This trial is being conducted at Hefei, China.

Who is sponsoring the NCT06565143 clinical trial?

NCT06565143 is sponsored by Anhui Medical University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology